HPV, Periodontitis Work In Tandem To Increase Risk Of Tongue Cancer

4/7/2008 Buffalo, NY staff ScienceDaily.com Persons with periodontitis who also are infected with human papillomavirus (HPV) are at increased risk of developing tongue cancer, new research conducted at the University at Buffalo School of Dental Medicine has shown. Periodontitis is a chronic inflammatory disease that destroys connective tissue and bone supporting the teeth. It has been associated with various systemic diseases, including diabetes and heart disease. Researchers from UB and Roswell Park Cancer Institute published the first study showing an association between long-standing periodontitis and risk of tongue cancer in the May 2007 issue of Archives of Otolaryngology - Head and Neck Surgery. Studies conducted elsewhere have found that HPV is an independent risk factor for a subset of head and neck cancers. The UB researchers now have shown that the two infections appear to work in tandem to boost the chances of developing tongue cancer. Mine Tezal, D.D.S., Ph.D., assistant professor in the Department of Oral Diagnostic Sciences, UB dental school, and research scientist at Roswell Park Cancer Institute, presented results of this research today (April 4, 2008) at the 2008 American Association of Dental research meeting in Dallas, Texas. Evidence of periodontitis-HPV synergy has important practical implications," said Tezal, "because there is a safe treatment for periodontitis, but no treatment for HPV infection. If these results are confirmed by other studies, this has a tremendous relevance in predicting and intervening in the initiation and prognosis of HPV-related diseases, including head and neck cancers." The study involved 30 patients [...]

2009-04-16T12:37:55-07:00April, 2008|Archive|

Salivary diagnostics, the ‘magic mirror’ to your health

4/6/2008 web-based article press release EurekAlert.com Accuracy, convenience, and non-invasiveness are the most critical characteristics for any diagnostic tool. A new concept, Salivaomics Knowledge Base (SKB), an in silico (i.e., performed on computer or via computer simulation) saliva diagnostic atlas, is launching today during the 37th Annual Meeting of the American Association for Dental Research in Dallas, Texas. With people increasingly adopting a ‘digital life’, the SKB will serve as a catalyst for future development and expansion of salivary diagnostics. For over three years, saliva has shown genuine promise as a diagnostic tool for oral cancer detection. As a result, the scientific community and general public have developed a keen interest in its value. Central to the SKB is the recent creation of two diagnostic alphabets in saliva, the proteome and the transcriptome. In the SKB, the salivary proteome and transcriptome are mapped to 23 human chromosomes, totaling1166 distinct proteins and 851 unique mRNA transcripts in saliva. The available information presently includes profiles from healthy males and females, as well as oral cancer patients. These profiles can be used to determine distinct differences between groups of interest. For example, if one wants to know the differences in the salivary protein or transcriptome profiles of males and females, the user-friendly interface can be utilized to retrieve information from the database. First, an overview of the biomarker distribution on the 23 human chromosomes can be determined. Then, one can zoom in on specific gene segments to extract more detailed information, all done [...]

2009-04-16T12:37:23-07:00April, 2008|Archive|

Curcumin Sensitizes Human Colorectal Cancer Xenografts

4/3/2008 Houston, TX Ajaikumar B. Kunnumakkara et al. linical Cancer Research 14, 2128-2136, April 1, 2008 Curcumin Sensitizes Human Colorectal Cancer Xenografts in Nude Mice to {gamma}-Radiation by Targeting Nuclear Factor-{kappa}B–Regulated Gene Products Purpose: How colorectal cancer develops resistance to {gamma}-radiation is not fully understood, but the transcription factor nuclear factor-{kappa}B (NF-{kappa}B) and NF-{kappa}B–regulated gene products have been proposed as mediators. Because curcumin, a component of turmeric (Curcuma longa), has been shown to suppress NF-{kappa}B activation, whether it can sensitize the colorectal cancer to {gamma}-radiation was investigated in colorectal cancer xenografts in nude mice. Experimental Design: We established HCT 116 xenograft in nude mice, randomized into four groups, and treated with vehicle (corn oil), curcumin, {gamma}-radiation, and curcumin in combination with {gamma}-radiation. NF-{kappa}B modulation was ascertained using electrophoretic mobility shift assay and immunohistochemistry. Markers of proliferation, angiogenesis, and invasion were monitored by immunohistochemistry and Western blot analysis. Results: Curcumin significantly enhanced the efficacy of fractionated radiation therapy by prolonging the time to tumor regrowth (P = 0.02) and by reducing the Ki-67 proliferation index (P < 0. 001). Moreover, curcumin suppressed NF-{kappa}B activity and the expression of NF-{kappa}B–regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase-9, and vascular endothelial growth factor), many of which were induced by radiation therapy and mediate radioresistance. The combination of curcumin and radiation therapy also suppressed angiogenesis, as indicated by a decrease in vascular endothelial growth factor and microvessel density (P = 0.002 versus radiation alone). Conclusion: Collectively, [...]

2009-04-16T12:37:01-07:00April, 2008|Archive|

Mounting Evidence Shows Red Wine Antioxidant Kills Cancer

4/2/2008 Rochester, NY staff Biocomare Life Science News (news.biocompare.com) Rochester researchers showed for the first time that a natural antioxidant found in grape skins and red wine can help destroy pancreatic cancer cells by reaching to the cell's core energy source, or mitochondria, and crippling its function. The study is published in the March edition of the journal, Advances in Experimental Medicine and Biology. The study also showed that when the pancreatic cancer cells were doubly assaulted -- pre-treated with the antioxidant, resveratrol, and irradiated -- the combination induced a type of cell death called apoptosis, an important goal of cancer therapy. The research has many implications for patients, said lead author Paul Okunieff, M.D., chief of Radiation Oncology at the James P. Wilmot Cancer Center at the University of Rochester Medical Center. Although red wine consumption during chemotherapy or radiation treatment has not been well studied, it is not "contraindicated," Okunieff said. In other words, if a patient already drinks red wine moderately, most physicians would not tell the patient to give it up during treatment. Perhaps a better choice, Okunieff said, would be to drink as much red or purple grape juice as desired. Yet despite widespread interest in antioxidants, some physicians are concerned antioxidants might end up protecting tumors. Okunieff's study showed there is little evidence to support that fear. In fact, the research suggests resveratrol not only reaches its intended target, injuring the nexus of malignant cells, but at the same time protects normal tissue from [...]

2009-04-16T12:36:26-07:00April, 2008|Archive|

Recurrent head and neck cancer: current treatment and future prospects

4/2/2008 web-based article PM Specenier and JB Vermorken Expert Rev Anticancer Ther, March 1, 2008; 8(3): 375-91 Recurrent and metastatic squamous cell carcinoma of the head and neck still carries a poor prognosis. Response rates with combination chemotherapy regimens are generally higher than those observed with single-agent chemotherapy. However, this did not translate into an overall survival benefit, not in even a single randomized trial. As none of the combination chemotherapy regimens demonstrated an overall survival benefit when compared with single-agent methotrexate, cisplatin or 5-fluorouracil, the use of combination chemotherapy outside clinical trials is usually restricted to younger patients with a good performance status and with symptomatic disease who require prompt symptom relief. After decades without real progress, a recent randomized trial showed that adding cetuximab, the first clinically available EGF receptor-directed monoclonal antibody, to a standard chemotherapy regimen (platinum/5-fluorouracil), led to an important survival benefit. In addition, the response rate nearly doubled with this approach, which has great promise for the treatment of symptomatic disease. There is now a plethora of targeted therapies in various stages of preclinical and clinical development. The next challenge will be to sort out which of them have a clinically meaningful activity and find out how to incorporate them into existing treatment regimens. Author's affiliation: Department of Medical Oncology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium

2009-04-16T12:36:04-07:00April, 2008|Archive|
Go to Top